Impact News +++ Gran Tierra outlines production exit rate target of up to 50,000 BOE/day with focus on free cash flow and... (SeekingAlpha) +++ GRAN TIERRA Aktie +3,75%

EDWARDS LIFESCIENCES Aktie

>EDWARDS LIFE Aktienkurs

72.64 EUR -1.9% (Tradegate)

Ask: 72.93 EUR / 420 Stück

Bid: 72.39 EUR / 420 Stück

Tagesumsatz: 1641 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

EDWARDS LIFE Aktie über LYNX handeln

Intraday

1 Jahr

>EDWARDS LIFE Performance

1 Woche: +13,2%

1 Monat: +12,2%

3 Monate: +5,4%

6 Monate: +12,7%

1 Jahr: +18,3%

laufendes Jahr: +3,3%

>EDWARDS LIFESCIENCES Aktie

Name:

EDWARDS LIFESCIENCES

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US28176E1082 / 936853

Symbol/ Ticker:

EWL (Frankfurt) / EW (NYSE)

Kürzel:

FRA:EWL, ETR:EWL, EWL:GR, NYSE:EW

Index:

S&P500

Webseite:

https://www.edwards.com/

Profil:

Edwards Lifesciences Corporation is a leading heal..
>Volltext..

Marktkapitalisierung:

41944.95 Mio. EUR

Unternehmenswert:

39137.12 Mio. EUR

Umsatz:

4911.94 Mio. EUR

EBITDA:

1467.25 Mio. EUR

Nettogewinn:

742.35 Mio. EUR

Gewinn je Aktie:

1.27 EUR

Schulden:

607.05 Mio. EUR

Liquide Mittel:

2828.74 Mio. EUR

Operativer Cashflow:

686.8 Mio. EUR

Bargeldquote:

2.89

Umsatzwachstum:

-13.83%

Gewinnwachstum:

-46.96%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

EDWARDS LIFESCIENCES, EDWARDS LIFE

Letzte Datenerhebung:

31.10.25

>EDWARDS LIFE Kennzahlen

Aktien/ Unternehmen:

Aktien: 587.1 Mio. St.

Frei handelbar: 97.95%

Leerverk. Aktien: 1.33%

Rückkaufquote: 2.36%

Mitarbeiter: 15800

Umsatz/Mitarb.: 0.3 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 4.29%

Bewertung:

KGV: 59.16

KGV lG: 33.95

KUV: 8.5

KBV: 4.83

PEG-Ratio: -

EV/EBITDA: 26.67

Rentabilität:

Bruttomarge: 78.13%

Gewinnmarge: 24.85%

Operative Marge: 27.2%

Managementeffizenz:

Gesamtkaprendite: 11.98%

Eigenkaprendite: 15.71%

>EDWARDS LIFE Peer Group

Es sind 596 Aktien bekannt.

>EDWARDS LIFE Chart & Kurs - NYSE

>EDWARDS LIFE News

31.10.25 - 16:45	EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash (Zacks)
	Edwards Lifesciences Q3 earnings and sales beat estimates on robust TAVR and TMTT growth, though margins take a sharp hit....

31.10.25 - 02:30	Edwards Lifesciences raises 2025 guidance to high end of 9–10% sales growth and $2.56–$2.62 EPS amid strong Q3 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 23:36	Edwards Lifesciences übertrifft Gewinnerwartungen für Q3 2025 (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 22:36	Edwards Lifesciences Corp. Q3 Profit Decreases, But Beats Estimates (AFX)
	WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) reported earnings for third quarter that Decreased from the same period last year but beat the Street estimates.The company's earnings came i......

30.10.25 - 21:33	Edwards Lifesciences CFO to step down by mid-2026 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 21:21	Edwards Lifesciences Non-GAAP EPS of $0.67 beats by $0.08, revenue of $1.55B beats by $50M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 21:18

Edwards Lifesciences Announces CFO Transition Plan (Business Wire)

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube. This news release includes forward-looking statements within the meaning of Section 27A of the ...

29.10.25 - 19:15	Edwards Lifesciences nabs upgrades from Jefferies, Wolfe (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.10.25 - 20:57	Edwards Lifesciences jumps on data for SAPIEN M3, EVOQUE valve replacements (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.10.25 - 19:42	Edwards Lifesciences-Aktie im Aufwind: Langzeitstudie belegt Vorteile der SAPIEN 3-Herzklappe (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

23.10.25 - 13:09

Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025 (Business Wire)

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube. Edwards, Edwards Lifesciences, and the ...

23.10.25 - 00:33	Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW (PR Newswire)
	NEW YORK, Oct. 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). If you currently own shares of Edwards stock, please......

17.10.25 - 16:00	Robust TAVR Growth to Drive Edwards Lifesciences′ Q3 Earnings (Zacks)
	Strong TAVR demand and expanding valve therapies are set to power EW's Q3 results despite lower EPS estimates....

12.10.25 - 14:39	Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW (PR Newswire)
	NEW YORK, Oct. 12, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). If you currently own shares of Edwards stock, please......

08.10.25 - 16:18	Edwards Lifesciences slips as Oppenheimer downgrades on upcoming data (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.10.25 - 19:24	Edwards Lifesciences upgraded at Evercore on upcoming ′topline inflection′ (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.10.25 - 00:45	Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW (PR Newswire)
	NEW YORK, Oct. 6, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). If you currently own shares of Edwards stock, please......

06.10.25 - 14:06	Heres What to Expect From Edwards Lifesciences′ Next Earnings Report (Barchart)
	Edwards Lifesciences is all set to release its fiscal third-quarter earnings later this month, and analysts project a double-digit earnings drop....

30.09.25 - 23:42	Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW (PR Newswire)
	NEW YORK, Sept. 30, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). If you currently own shares of Edwards stock, please......

30.09.25 - 03:15	Heres How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years (Benzinga)
	Edwards Lifesciences (NYSE: EW) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an average annual return of 16.53%. Currently, Edwards Lifesciences has a market capitalization of $45.32 billion. read more...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Lehrling hört mit Bangigkeit die sich kreuzenden Stimmen. Es scheint ihm jede Recht zu haben, und eine sonderbare Verwirrung bemächtigt sich seines Gemüts. - Novalis

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram